News

Health insurance company Oscar Health (NYSE:OSCR) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 70.4% year on year to $4.88 billion. Its non-GAAP profit of $1.10 per share was significantly above analysts’ consensus estimates.

Oscar Health (NYSE:OSCR) reported record profitability for the first half of 2026 and raised its full-year operating outlook, citing membership growth, disciplined pricing, favorable utilization trends and lower administrative expense ratios. Chief Executive Officer Mark Bertolini said the company

Revenue surged 70% as membership grew 46% and operating margins hit record lows.

Oscar Health Inc (OSCR) delivers a stellar Q2 with revenue up 70% and net income of $362 million, prompting a $250 million increase to full-year earnings guidance.

Moby summary of Oscar Health, Inc.'s Q2 2026 earnings call

Oscar Health reported second-quarter 2026 results showing a shift from a prior-year loss to net income of US$361.81 million and lifted its full-year 2026 guidance to total revenue of US$18.70–US$19.00 billion and earnings from operations of US$500–US$700 million. This combination of a profit turnaround and a sizeable upgrade to operating earnings expectations suggests Oscar’s underlying operations are running more efficiently than previously anticipated. We’ll now examine how Oscar’s...

Oscar Health dived Thursday morning, despite reporting better-than-expected earnings and raising its full-year outlook. Oscar said it sees more tailwinds than headwinds based on what it knows. Shifts in the ACA Marketplace due to the surge in premiums related to the end of enhanced government subsidies have transformed the market.

Although the revenue and EPS for Oscar Health (OSCR) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Oscar Health (OSCR) delivered earnings and revenue surprises of +155.81% and -0.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Health insurance company Oscar Health (NYSE:OSCR) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 70.4% year on year to $4.88 billion. Its GAAP profit of $1.10 per share was significantly above analysts’ consensus estimates.

SANM, OSCR and PENN made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 6th, 2026.

Investors pay particular attention to a health insurer’s second-quarter report, which reflects more medical claims data among members.

Octave Specialty heads into Q2 results with revenues projected to jump 47.4%. The bottom line is likely to improve y/y, though the model does not signal a beat.

PRU's Q2 results are expected to reflect strength in Retirement, Individual Life and PGIM despite pressure in Group Insurance.

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

AIZ's Q2 results are expected to benefit from growth in Global Housing and Global Lifestyle, supported by higher premiums and investment income.

Oscar Health (OSCR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

In the latest trading session, Oscar Health, Inc. (OSCR) closed at $30.57, marking a -2.64% move from the previous day.

Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?

S&P 500 health insurer Centene blew away Q2 earnings forecasts amid lower-than-expected Affordable Care Act Marketplace benefit costs. CNC stock initially moved higher, but shares reversed sharply lower as the company discussed its outlook, including slightly higher Medicaid attrition and a more costly covered population in the second half of 2026. Centene posted Q2 earnings of $2.51 a share, crushing forecasts of $1.09 by $1.42 a share.

The past six months have been a windfall for Oscar Health’s shareholders. The company’s stock price has jumped 86.2%, hitting $27.70 per share. This performance may have investors wondering how to approach the situation.

Oscar Health (OSCR) has been drawing attention after a strong share price run, with investors weighing that performance against mixed valuation signals that suggest the stock is not an obvious bargain. See our latest analysis for Oscar Health. Recent trading has cooled slightly, with the share price down around 3% over the past month and 7 days. That comes after a strong 90 day share price return of about 68% and a very large 3 year total shareholder return, suggesting momentum has been...

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.

Oscar Health stock has delivered very strong returns over the past few years, yet the valuation checks present a more mixed picture that stops short of calling it a straightforward bargain. The share price has returned 269.8% over the last 3 years, which puts recent short term pullbacks into the context of a powerful longer term move. Investor expectations around Oscar Health's ability to scale its insurance platform efficiently can support the current valuation, while ongoing execution...

Oscar Health, Inc. (OSCR) reached $29.5 at the closing of the latest trading day, reflecting a -4.13% change compared to its last close.

Goosehead (GSHD) delivered earnings and revenue surprises of +23.08% and +9.70%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Solid retention, renewals, prudent pricing, exposure growth and improved digitization are expected to help CINF, RGA, OSCR, WTW and AFL outperform Q2 estimates.

Zacks.com users have recently been watching Oscar Health (OSCR) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Oscar Health (OSCR) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the resilience and financial flexibility of large-cap firms, making careful selection crucial.